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Abstract
Cigarette smoking has been associated with dementia and dementia-related brain changes, notably gray matter (GM)
volume atrophy. These associations are thought to reﬂect the co-morbidity of smoking and vascular, respiratory, and
substance use/psychological conditions. However, the extent and localization of the smoking-GM relationship and the
degree to which vascular, respiratory, and substance use/psychological factors inﬂuence this relationship remain
unclear. In the Coronary Artery Risk Development in Young Adults CARDIA cohort (n= 698; 52% women; 40% black
participants; age= 50.3 (SD= 3.5)), we examined the associations of smoking status with total GM volume and GM
volume of brain regions linked to neurocognitive and addiction disorders. Linear regression models were used to
adjust for vascular, respiratory, and substance use/psychological factors and to examine whether they modify the
smoking-GM relationship. Compared to never-smokers, current smokers had smaller total GM volume (−8.86 cm3 (95%
CI=−13.44, −4.29). Adjustment for substance use/psychological – but not vascular or respiratory – factors
substantially attenuated this association (coefﬁcients=−5.54 (95% CI=−10.32, −0.76); −8.33 (95% CI=−12.94,
−3.72); −7.69 (95% CI=−6.95, −4.21), respectively). There was an interaction between smoking and alcohol use such
that among alcohol non-users, smoking was not related to GM volumes and among alcohol users, those who currently
smoked had −12 cm3 smaller total GM, speciﬁcally in the frontal and temporal lobes, amygdala, cingulate, and insula.
Results suggest a large-magnitude association between smoking and smaller GM volume at middle age, accounting
for vascular, respiratory, and substance use/psychological factors, and that the association was strongest in alcohol
users. Regions suggested to be most vulnerable are those where cognition and addiction processes overlap.
Introduction
Cigarette smoking has been associated with higher risk
of cognitive decline and dementia in older adults1–4.
Although the mechanisms are not fully understood, these
associations are predominantly thought to arise from
accumulated smoking-related damage to cardiovascular
and respiratory processes in the brain1,2,5,6. Parallel to its
established impact on vascular and respiratory functions,
tobacco dependence is the most prevalent substance-
dependence disorder and frequently co-occurs with psy-
chiatric conditions such as mood and substance use dis-
orders7–9. For instance, among persons with alcohol abuse
disorder, smoking prevalence has been estimated to be as
high as 90%10,11.
In line with its documented effects on cardiovascular
health, some imaging studies have reported that smoking
is related to compromised vascular and circulation pro-
cesses in the brain, including changes in perfusion and
white matter (WM) lesions4,12–14. One consistent ﬁnding
from imaging studies is that smokers have smaller total
brain volume4,12,15, and smaller gray matter (GM) volume
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in particular, compared to never-smokers6,16. Interest-
ingly, several results show that this association may be
differentially localized16,17, suggesting that more direct
links between smoking and speciﬁc brain structures could
be underlying the associations of smoking to functional
outcomes such as addiction and cognitive functioning.
However, ﬁndings on which brain structures may pre-
ferentially be affected by smoking are heterogeneous. The
discrepancy could be explained by methodological lim-
itations. One limitation of published studies is that they
were mostly conducted in small (often fewer than
100 subjects)15,16 and selective samples (based on parti-
cipants with several morbidities)18,19. Further, studies in
community-dwelling individuals have focused mainly on
older populations and thus may have had limited ability to
disentangle the primary brain changes associated with
smoking from those resulting from general accumulated
damage such as advanced forms of cardiovascular dis-
ease4,5,20. Another main limitation is that prior studies
included limited adjustment for important contributing
factors, such as cardiovascular, respiratory, and substance
use/psychological factors17. Given their high co-
occurrence and complex relationships with smoking and
GM, the role of these factors warrants careful
investigation1,2,5,11,21.
In this study, we used a community-based sample of
middle-aged adults to assess the associations of smoking
with total brain GM volume and with volumes of candi-
date brain regions linked to cognitive impairment and
addictive behaviors, while assessing the role of vascular,
respiratory, and substance use/psychological factors. We
ﬁrst adjusted for these factors and then tested whether
they modiﬁed the smoking-GM relationship. We hypo-
thesized that GM volumes would be smaller in smokers,
particularly in smokers with additional vascular risk fac-
tors and addiction-related behaviors.
Materials and methods
Study sample
The Coronary Artery Risk Development in Young
Adults (CARDIA) study is a population-based long-
itudinal study of the determinants of cardiovascular dis-
ease in young black and white adults22. At baseline
(1985–1986), the study recruited 5115 participants aged
18–30 years randomly selected by telephone numbers
from census tracts in four US cities (Birmingham, Ala-
bama; Chicago, Illinois; Minneapolis, Minnesota; and
Oakland, California); the sample was balanced by race
(black, white), sex, and education (high school degree
or less, higher than high school). Participants were fol-
lowed for 25 years (with examinations at year 2, 5, 7, 10,
15, 20, and 25 of follow-up); 72% (n= 3499) of the sur-
viving baseline cohort participated in the 25th year
examination.
At the 25th year examination, a sub-sample took part in
the CARDIA brain magnetic resonance imaging (MRI)
sub-study. That sub-study enrolled participants from
three CARDIA ﬁeld centers (Birmingham, Minneapolis,
and Oakland) and aimed to achieve a balanced sample
within sex-race groups. Exclusion criteria were a contra-
indication to MRI or a body size too large for the MRI
tube bore. In total, 719 subjects participated in the MRI
sub-study.
CARDIA is annually approved by the institutional
review boards at each site (the Institutional Review Board
of the University of Minnesota, the Kaiser Permanente
Northern California Institutional Review Board, Uni-
versity of Pennsylvania Institutional Review Board, The
University of Alabama Birmingham Institutional Review
Board, and the NIH Ofﬁce of Human Subjects Research
Protection for the Intramural Research Program, National
Institute on Aging); separate approval was obtained for
the brain MRI study. Each participant provided written
informed consent at each exam12.
Brain MRI data
Brain MRIs were acquired using 3-T MR scanners
(Oakland: Siemens 3 T Tim Trio/VB 15 platform; Min-
nesota: Siemens 3 T Tim Trio/VB 15 platform; and Ala-
bama: Philips 3 T Achieva/2.6.3.6 platform). In
collaboration with the MRI reading center at the Uni-
versity of Pennsylvania (Section of Biomedical Image
Analysis, Department of Radiology), each MRI ﬁeld center
performed the MRI scans and transferred the data to the
reading center, according to standardized procedures and
following standard quality assurance protocols, previously
described12. Brain tissue volumes were estimated from the
sagittal 3D T1 sequence (Plane Sagittal Coil 12channel
File name 3D T1 MPRAGE: Tr 1900 Te 2.89 Fov 250mm,
thickness 1 mm slices 176 slices, Base Res 255, Phase res
100%, Matrix 256 × 256 NSA 1 TI 900ms Pixel BW
170hz. ETL= 1 Flip= 9).
Image processing, quality control checks, and auto-
mated brain tissue volume computations were all per-
formed at the MRI reading center following standardized
protocols12,23–26. First, all imaging data were converted to
Neuroimaging Informatics Technology Initiative (NIFTI)
format. Initial quality control (QC) was performed
through manual inspection of each subject’s T1 scan for
motion artifacts and other quality issues. The preproces-
sing of the T1-weighted scan involved brain extraction
(i.e., the removal of the skull, extra-cerebral tissues and
cerebellum) using a multi-atlas segmentation method27,
correction of image inhomogeneities28, and segmentation
of the brain parenchyma into GM, WM and cerebrospinal
ﬂuid29. Brain tissue was segmented into anatomical
regions by transferring expert deﬁned region of interest
(ROI) labels on a standard template image space to the
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subject T1 space through non-linear registration23. GM
and WM were classiﬁed into regions of interest according
to the Jakob atlas30 and further into normal and abnormal
and tissue. Within each ROI, GM and WM volumetric
measurements are calculated. Total brain volume was
obtained by summing GM and WM volumes; total
intracranial volume was the sum of GM, WM, and cere-
bral spinal ﬂuid volumes.
Here, we assessed the associations of smoking with total
GM volume, and as a comparison with total brain tissue
and total WM volume. We examined associations with
lobar GM to assess whether smoking had a global com-
pared to speciﬁc association with GM. We also assessed
the relationship of smoking with GM volumes in speciﬁc
brain structures. These regions have been linked to
dementia and cognitive impairment and to addiction
disorders and have been implicated in memory, learning
and cognition as well as emotion and reward processes:
hippocampus (memory and emotion regulation), para-
hippocampal gyrus (memory encoding and recall),
entorhinal cortex (memory), precuneus (memory and
cognition), cuneus (visual processing and inhibitory con-
trol), thalamus (perception, sensory, and motor pro-
cesses), caudate (motor, learning, and reward processes),
putamen (movement and learning), nucleus accumbens
(reward), cingulate (emotion and behavior regulation),
insula (emotional experience and perception), and the
amygdala (affective processing and emotional mem-
ory)21,31–35.
Smoking data
Smoking data were collected with the same interviewer-
based questionnaire administered at each study exam-
ination. Participants were asked if they have ever smoked
regularly (deﬁned as at least 5 cigarettes per week, almost
every week) for at least three months. If they answered no,
they were classiﬁed as never-smoker at that study wave. If
they answered yes, participants were then asked whether
they currently smoked regularly (at least ﬁve cigarettes per
week, almost every week) for at least three months; par-
ticipants were classiﬁed as current smokers if they
answered yes, and as former smokers if they reported no
current regular cigarette smoking.
Mid-life smoking status was based on self-reported
status (never, former, current) at year 25. This self-report
was veriﬁed against prior data from earlier study exams;
for most participants, self-reported status was consistent
across study waves, and for 57 (8.7%) subjects who
reported being never-smokers at Year 25, we re-coded
them as former-smokers because they had reported being
smokers or former-smokers at multiple previous study
exams.
Covariates
All analyses were adjusted for age, race (black/white),
educational attainment (≤high school diploma, >high
school diploma), total intracranial volume, and study
center. We then incorporated data on several factors
combined into three groups, representing three mechan-
isms and pathways that are hypothesized to act as con-
founders or mediators of the smoking-GM volume
relationship: vascular, respiratory, and substance use/
psychological factors.
Vascular risk factors included body mass index, history
of hypertension (deﬁned as current or prior occurrence of:
diastolic blood pressure ≥90 and/or systolic blood pres-
sure ≥ 140mmHg and/or taking antihypertensive medica-
tion), cerebro/vascular events (yes/no variable indicating
self-reported occurrence of any of the following: heart
attack, angina, heart failure, rheumatic heart disease,
mitral valve prolapse, stroke and peripheral vascular dis-
ease), history of diabetes (deﬁned following ADA criteria
for levels of fasting, non-fasting or postprandial OGTT
results, HbA1c percent, or use of anti-diabetes medica-
tion), and hypercholesterolemia (total cholesterol ≥
240mg/DL and/or use of cholesterol lowering
medication).
Respiratory factors were history of respiratory illness
(deﬁned as current or prior self-reported occurrence of
asthma, tuberculosis, chronic bronchitis, chronic
obstructive pulmonary disease, emphysema, or use of
medication for asthma or for breathing problems), and
forced expiratory volume (FEV1 estimated at 1 sec, in
liters, and measured using a spirometer).
Substance use/psychological factors investigated were
self-reported lifetime illicit drug use (yes/no for having
ever-used any of the following: marijuana, amphetamines,
methamphetamines, cocaine, crack, heroin, or pain-killers
for non-medical reasons), depressive symptoms (Center
for Epidemiologic Studies – Depression; CES-D) scale36,
and alcohol consumption, which was based on questions
regarding the usual number of alcoholic beverages (wine,
beer, or hard liquor) consumed per week; assuming that
one drink of beer, wine, or liquor contains 16.7, 17.0, and
19.1 milliliters (mL) of ethanol respectively (as per
CARDIA protocol), we computed total consumption per
week in mL of ethanol and divided it by 17.24 mL of
ethanol per average drink to estimate the usual number of
drinks per week. Accordingly, alcohol consumption was
classiﬁed as no alcohol use (no consumption of alcohol
beverages), high-risk alcohol use (based on the sex-
speciﬁc weekly maximum drinking limits published by the
National Institute on Alcohol Abuse and Alcoholism (for
men > 14, women > 7 standard drinks/week)), and low-
risk alcohol use (>0 and ≤7 drinks for women and >0 and
≤14 drinks for men).
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FEV1 measures were collected at the year 20 exam, the
study visit prior to the MRI. For all other covariates, we
used their values at the time of the MRI (year 25 exam).
In sensitivity analyses, we also included adjustment for
cancer history (current or previous occurrence of cancer
and tumor) and physical activity (measured at year 25
using physical activity scores expressed in exercise units,
calculated based on the reported frequency and intensity
of participation in 13 categories of moderate and vigorous
recreational sports, exercise, leisure, and occupational
activities over the prior 12 months)37. Since results did
not change with these adjustments, data are not shown.
Statistical analyses
Of the 719 subjects with MRI data, 698 had complete
data on smoking and potential covariates, and 643 had
data on FEV1. Total and regional GM volumes were
normally distributed. Multivariable linear regression
models were used to examine their relationships with
mid-life smoking status at the time of the MRI. In all
analyses, we adjusted for basic covariates (age, sex, race,
educational attainment, intracranial volume, and study
centers). We systematically examined the role of other
potentially important covariates by using three models,
one adjusting for vascular factors, one for respiratory
factors, and one for substance use/psychological factors.
Then, we tested, using interaction terms, whether these
factors modiﬁed the associations of smoking and GM
volumes and conducted stratiﬁed analyses to examine
signiﬁcant interactions. We primarily focused on other
vascular risk factors— which often co-occur with smoking
and might inﬂuence smoking behavior and its out-
comes6,12,38— and on alcohol use, given its high co-
morbidity with smoking and emerging ﬁndings regarding
their interactions11,19,39.
Given the high prevalence of self-reported ever-use of
marijuana (Supplementary Table S1), we assessed in
sensitivity analyses, whether there was a change in results
after adjusting for or testing for effect modiﬁcation by the
lifetime use (yes/no) of marijuana and by the lifetime
extent of marijuana use (the number of times participants
reported using marijuana up to study year 25 (classiﬁed
into ≤2, 3 to 10, 11 to 99, 100 to 499, and ≥500 times)); we
saw no signiﬁcant difference in the conclusions.
In additional analyses, we evaluated the relationship of
indicators of smoking history (cumulative pack-years, age
at start of smoking, and years of smoking cessation) and
GM outcomes among ever-smokers.
All analyses tested two-tailed hypotheses with a sig-
niﬁcance level of 0.05. Analyses were completed using SAS
version 9.3 (SAS Institute, Cary, NC). Data and statistical
codes are available from the CARDIA Coordinating Cen-
ter: http://www.cardia.dopm.uab.edu/contact-cardia.
Results
Compared to never and former smokers, current
smokers were younger and had the highest proportion
of black participants, the lowest educational attainment,
and the highest prevalence of hypertension (Table 1).
Other cardiovascular risk factors were not different
across smoking groups (Table 1). Current smokers had
the highest frequency of respiratory illnesses and the
lowest FEV1. All substance use/psychological measures
were more frequent in smokers (Table 1): compared
to never-smokers, current and former-smokers had
higher prevalence of high-risk alcohol drinking and
illicit drug use; current smokers had more depressive
symptoms.
Smoking and GM volume
Brain volumes are presented in Supplementary Table
S2. Compared to never-smokers, current smokers had
signiﬁcantly smaller total GM volume (−8.86 cm3 (95%
CI=−13.44, −4.29); Table 2). There were no differ-
ences in total white matter volume across smoking
groups; the trend of smaller total brain volume in
smokers reﬂected the association between smoking and
smaller GM (Table 2).
Adjustment for vascular and respiratory factors
Adjusting for vascular or respiratory factors slightly
attenuated the associations of smoking and total GM
volume (with a 6 to 13% change in the smoking-GM
volume estimated association; Table 2). There was no
indication of interaction between smoking and vascular or
respiratory factors in the smoking-GM relationship.
Adjustment for substance use/psychological factors
The smoking-total GM association was substantially
attenuated (from −8.86 to −5.54 cm3; 37% change in
estimate) when the model included substance use/psy-
chological factors (Table 2).
Similar patterns were found in the lobar (Supple-
mentary Table S3) and candidate region analyses
(Supplementary Table S4): Current smokers had sig-
niﬁcantly smaller GM volume in the temporal, occipital,
and frontal lobes, and in the amygdala, entorhinal
cortex, cingulate, and insula, compared to never-smo-
kers; these associations were largely attenuated when
substance use/psychological factors were taken into
account. Former-smokers had a trend for smaller GM
volume but they were not signiﬁcantly different than
never-smokers.
Other candidate regions (hippocampus, para-
hippocampal gyrus, cuneus, precuneus, thalamus, cau-
date, putamen, and the nucleus accumbens) were not
related to smoking status (Supplementary Table S4).
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Interactions between substance use/psychological factors,
smoking, and brain volumes
In the substance use/psychological factors model, all
factors showed associations with GM volume: high-risk
alcohol drinking (coefﬁcient=−5.58 cm3 (95% CI=
−10.57, −1.14)) and higher CES-D scores (−0.24 cm3
(95% CI=−0.46, −0.02) per unit increase in CES-D
score) were associated with signiﬁcantly smaller total GM;
illicit drug use was associated with smaller GM (coefﬁ-
cient=−3.69; p= 0.07).
Illicit drug use and depressive symptoms did not modify
the association between smoking and GM volumes (p >
0.3 for interaction terms). There was a signiﬁcant inter-
action between alcohol use and smoking indicating that
the association is differentially observed in alcohol users
(p for interaction of current smoking with high-risk
alcohol use= 0.03 and p= 0.07 for interaction with low-
risk alcohol use). Details regarding the distribution of
sample’s characteristics across alcohol use sub-groups are
presented in Supplementary Table S5.
Alcohol use, smoking, and brain volumes
Results of GM volumes across smoking and alcohol use
groups (Table 3) show that subjects who don’t use alcohol
(irrespective of smoking status) and never-smokers
(whether alcohol users or not) do not have different
GM volumes (with adjusted mean GM volumes ranging
from 516 to 520 cm3). However, the combination of
current alcohol (both low- and high-risk use) and smok-
ing use was negatively associated with GM volume (Table
3); therefore, we grouped participants into alcohol non-
users vs. subjects reporting any alcohol use (low-risk and
high-risk). Among participants who do not use alcohol,
smoking was not associated with total or regional GM
volumes (Table 4). In contrast, among alcohol users (light
and heavy-risk combined), those who currently smoked
had −12 cm3 smaller total GM volume, and speciﬁcally
smaller frontal, temporal, amygdala, cingulate, and insula
GM volumes, even after accounting for other substance
use /psychological, vascular, and respiratory factors
(Table 4). There was a trend toward an association of
smoking to smaller occipital GM volume (p= 0.11).
Similar to analyses in the total sample, volumes of other
candidate structures of interest were not related to
smoking in the stratiﬁed analyses (p > 0.17; data not
shown).
In additional analyses (Supplementary Table S6) inves-
tigating the associations of GM volumes to smoking
Table 1 Characteristics of the CARDIA-MRI sample by smoking status at Year 25
Mean (SD) or n (%)
Never-smoker n= 362 Former-smokers n= 219 Current smokers n= 117
Age at MRI 50.18 (3.61) 50.82 (3.27) 49.63 (3.57)*
Gender (Women) 189 (52.2%) 120 (54.8%) 57 (48.7%)
Race (Black) 143 (39.5%) 68 (31.1%) 68 (58.1%)*
Educational attainment ( ≤ high school) 48 (13.3%) 52 (23.7%) 49 (41.9%)*
Self-reported history of vascular disease 42 (11.6%) 28 (12.8%) 19 (16.2%)
Hypertension 97 (26.8%) 76 (34.7%) 56 (47.9%)*
Diabetes 35 (9.7%) 22 (10.0%) 16 (13.9%)
Body mass index 28.68 (5.59) 28.86 (5.97) 29.28 (5.80)
High cholesterol 72 (19.9%) 49 (22.4%) 25 (21.4%)
History of respiratory illnesses 51 (14.1%) 42 (19.2%) 33 (28.2%)*
Forced expiratory volume (FEV1)
a 3.12 (0.79) 3.15 (0.77) 2.96 (0.73)
Alcohol consumption
Non-user 159 (43.1%) 92 (41.6%) 38 (33.0%)
Low-risk alcohol use 167 (46.1%) 85 (38.8%) 42 (35.9%)
High-risk alcohol use 39 (10.77%) 42 (19.2%) 37 (31.6%)*
History of illicit drug use 223 (61.60%) 196 (89.5%) 100 (85.5%)*
Depressive symptoms (CES-D) 8.01 (6.80) 8.73 (6.90) 11.41 (8.36)*
*p < 0.01; p-values obtained using chi-square tests for comparing categorical variables and ANOVA tests for comparing continuous tests across smoking groups
aForces expiratory volume measured at Year 20 and for n= 643 subjects, all other covariate measures at Year 25 and for n= 698 subjects
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characteristics (cumulative pack-years, age at start of
smoking, and years since smoking cessation), the inter-
action between alcohol use and smoking characteristics
were weaker than for smoking status (p-values for inter-
action terms > 0.09); however, in general, associations
between smoking characteristics and GM outcomes were
more pronounced in alcohol users. Higher cumulative
pack-years and younger age at smoking initiation were
associated with smaller total GM (p= 0.11 and p= 0.07,
respectively); associations with age at smoking initiation
were more pronounced for amygdala and temporal GM
volumes (p= 0.06 and 0.02, respectively).
Discussion
In community-dwelling middle-aged adults, current
smoking was associated with smaller total and regional
GM volumes. Importantly, results suggest that substance
use/psychological —but not vascular or respiratory—
factors substantially inﬂuenced these associations. In
particular, the association of smoking and GM volumes
was different in alcohol users and non-users: subjects who
did not use alcohol showed no association between
smoking and GM volumes, whereas among alcohol users,
those who smoked had signiﬁcantly smaller total and
regional GM volumes compared to never-smokers.
Table 2 Smoking status and global brain volumes in the CARDIA brain MRI cohort
Total brain volume Total white matter volume Total gray matter volume
Beta 95% CI p Beta 95% CI p Beta 95% CI p
Basic model: demographics, intracranial volume
Never-smokers Ref. Ref. Ref.
Former-smokers −1.72 −6.55, 3.10 0.49 1.80 −2.25, 5.86 0.38 −3.52 −7.12, 0.07 0.05
Current smokers −9.23 −15.38, −3.09 0.003 −0.37 −5.53, 4.79 0.89 −8.86 −13.44, −4.29 0.0002
Vascular factors model: demographics, intracranial volume, vascular risk factors
Never-smokers Ref. Ref. Ref.
Former-smokers −1.04 −6.21, 3.41 0.57 1.95 −.118, 6.02 0.35 −3.35 −6.95, 0.25 0.07
Current smokers −8.36 −14.53, −2.19 0.008 −0.030 −5.24, 5.18 0.99 −8.33 −12.94, −3.72 0.0004
Respiratory factors model: demographics, intracranial volume, respiratory factors (respiratory illnesses+ FEV1)
Never-smokers Ref. Ref. Ref.
Former-smokers −1.58 −6.57, 3.41 0.54 1.58 −2.62, 5.77 0.46 −3.15 −6.88, 0.58 0.10
Current smokers −9.06 −15.69, −2.42 0.008 −1.37 −6.95, 4.21 0.63 −7.69 −6.95, 4.21 0.002
Substance use/psychological factors model: demographics, intracranial volume, substance use/psychological factors
Never-smokers Ref. Ref. Ref.
Former-smokers 0.24 −4.78, 5.27 0.93 2.04 −2.23, 6.30 0.35 −1.80 −5.52, 1.93 0.34
Current smokers −5.24 −11.69, 1.21 0.11 0.30 −5.18, 5.77 0.92 −5.54 −10.32, −0.76 0.02
Basic model adjusted for age, sex, education, race, study center, and total intracranial volume, n= 698
Vascular factors model adjusted for age, sex, education, study center, race, and total intracranial volume, hypertension, diabetes, history of vascular disorders, BMI, and
high cholesterol, n= 698
Respiratory factors adjusted for age, sex, education, race, study center, and total intracranial volume, respiratory illness, and FEV1, n= 643 (sub-sample with spirometer
data)
Substance use/psychological factors model adjusted for age, sex, education, race, and total intracranial volume, alcohol consumption, depressive symptoms, and illicit
drug use, n= 698
Bold values: We were highlighting the statistically signiﬁcant results
Table 3 Brain gray matter volume across alcohol and smoking groups in the CARDIA brain MRI cohort
Alcohol non-users Light-risk alcohol users High-risk alcohol users
n Betaa (95% CI) Meanb (SE) n Betaa (95% CI) Meanb (SE) n Betaa (95% CI) Meanb (SE)
Never-smokers 156 Ref. 518.44 (1.85) 167 Ref. 520.26 (1.72) 39 Ref. 516.02 (3.54)
Former-smokers 92 −2.32 (−8.79, 4.15) 516.36 (2.38) 85 −0.38 (−6.39, 5.62) 519.69 (2.38) 42 −6.52 (−15.92, 2.88) 512.04 (3.33)
Current smokers 38 3.28 (−5.53, 12.09) 520.50 (3.83) 42 −11.65 (−23.05, −0.26) 511.85 (3.49) 37 −11.11 (−19.60, −2.63) 506.96 (3.91)
aCoefﬁcients and 95% conﬁdence intervals (95% CI)
badjusted means and standard errors (SE) estimated using fully-adjusted linear regression models including age, sex, education, race, study center, total intracranial
volume, hypertension, diabetes, history of vascular disorders, BMI, high cholesterol, respiratory illness, FEV1, depressive symptoms, and illicit drug use
bAdjusted means and standard errors
Bold values: We were highlighting the statistically signiﬁcant results
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Table 4 Smoking status and total and regional gray matter volumes, stratiﬁed by alcohol use, in the CARDIA brain MRI
cohort
Alcohol non-users Low/high-risk alcohol users
βa 95% CI p βa 95% CI p
Total GM
Never-smokers Ref. Ref.
Former-smokers −2.32 −8.79, 4.15 0.48 −2.69 −7.63, 2.24 0.28
Current smokers 3.28 −5.53,12.09 0.46 −12.01 −18.54, −5.48 0.0003
Frontal GM
Never-smokers Ref. Ref.
Former-smokers −0.48 −3.31, 2.17 0.72 −1.56 −3.62, 0.49 0.14
Current smokers 1.60 −2.01, 5.21 0.38 −3.57 −6.28, −0.85 0.01
Temporal GM
Never-smokers Ref. Ref.
Former-smokers −0.48 −2.76, 1.79 0.68 −1.51 −3.25, 0.24 0.09
Current smokers 0.24 −2.86, 3.34 0.88 −4.14 −6.45, −1.84 0.0005
Occipital GM
Never-smokers Ref. Ref.
Former-smokers −0.57 −2.07, 0.93 0.46 0.66 −0.46, 1.78 0.25
Current smokers −0.01 −2.06, 2.03 0.99 −1.22 −2.70, 0.27 0.11
Parietal GM
Never-smokers Ref. Ref.
Former-smokers −0.04 −1.69, 1.61 0.96 −0.19 −1.49, 1.11 0.77
Current smokers 1.15 −1.10, 3.40 0.32 −0.84 −2.56, 0.88 0.34
Amygdala
Never-smokers Ref. Ref.
Former-smokers −0.02 −0.11, 0.07 0.64 −0.02 −0.09, 0.04 0.50
Current smokers −0.02 −0.14, 0.10 0.75 −0.10 −0.18, −0.01 0.03
Insula
Never-smokers Ref. Ref.
Former-smokers −0.13 −0.554 0.30 0.56 −0.16 −0.47, 0.16 0.32
Current smokers 0.34 −0.25, 0.92 0.26 −0.70 −1.12, −0.28 0.001
Entorhinal cortex
Never-smokers Ref. Ref.
Former-smokers 0.04 −0.06, 0.15 0.43 −0.06 −0.14, 0.02 0.15
Current smokers −0.10 −0.25, 0.05 0.18 −0.06 −0.17, 0.04 0.26
Cingulate
Never-smokers Ref. Ref.
Former-smokers −0.24 −0.89, 0.42 0.48 0.004 −0.52, 0.53 0.99
Current smokers −0.15 −1.05, 0.75 0.74 −1.17 −1.87, −0.48 0.001
aCoefﬁcients estimated using fully-adjusted linear regression models including age, sex, education, race, study center, total intracranial volume, hypertension,
diabetes, history of vascular disorders, BMI, high cholesterol, respiratory illness, FEV1, depressive symptoms, and illicit drug use
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Regionally, this association was observed in the temporal
and frontal lobes and in the amygdala, cingulate, and
insula.
In line with other reports mainly in smaller samples40,
we found that current smoking was associated with
smaller total GM volume but not WM volume6,15,16. This
association was speciﬁcally observed in alcohol users and
the difference in GM volume of −12 cm3 in current
smokers compared to never-smokers in this sub-group
was large: roughly equivalent to a decade difference in age
in our sample (age was associated with 1.2 cm3 smaller
volume per year). Results indicate the importance of co-
occurring smoking and alcohol use with respect to GM
volumes and identify low-risk and high-risk alcohol users
in a community-based sample as an “at-risk” subgroup for
the potential negative neurocognitive sequelae of
smoking.
It has been hypothesized and shown in older cohorts
that vascular and respiratory factors may play an impor-
tant role in the relationship between cigarette smoking
and GM5. But in this younger cohort, these factors were
not strongly related to concurrent smoking status and did
not signiﬁcantly modify the smoking-GM association.
Adjusting for these factors only slightly attenuated the
estimates of the smoking-GM association, though greater
attenuation was observed in the model adjusted for
respiratory factors, notably FEV1; this might be expected,
as FEV1 is likely to be a mediating factor of the actions of
smoking5. Our results suggest that, at middle-age, sub-
stance use/psychological factors are more important for
how smoking relates to GM volume. Adding each of
depressive symptoms, alcohol use, or illicit drug use alone
slightly attenuated the smoking-GM relationship (to −7
or −8 cm3), but together these correlated factors (as seen
in Table 1 and Table S5) had a substantial inﬂuence on
the relationship (Table 2). Importantly, the association of
smoking with GM varied depending on alcohol use,
accounting for depressive symptoms and illicit drug use
(Tables 3 and 4). As was found for smoking, there was no
evidence for an interaction between alcohol use and illicit
drug use or depressive symptoms with regards to GM
volume (data not shown) suggesting that the alcohol-
smoking interplay might be distinctively noticeable and
important for GM volume.
Findings from studies on alcohol use disorder have
shown an intricate interplay between smoking and alcohol
use. Smoking has been linked to the severity of alcohol
abuse and to a lower success rate of recovery interven-
tions11,41. Alcohol use disorder has been independently
associated with several negative functional and structural
brain outcomes, including higher risk of dementia, poorer
cognitive function, metabolic abnormalities, and smaller
global and regional GM volumes11,19,41. Smoking has been
found to aggravate some of these outcomes and to
suppress metabolic, neuronal, and functional recovery of
abstinence interventions11,41. Our results complement
these ﬁndings in adults with alcohol abuse disorder, and
show that both low- and high-risk alcohol users in a
community-based sample presented adverse associations
between smoking and GM volumes.
Regionally, associations were observed with smaller
frontal and temporal GM volume in our sample, a ﬁnding
consistent with other studies of smoking in both younger
and older samples5,16,17,42, and with studies of other
substance use disorders11,21,43–45. Smoking was also
associated with signiﬁcantly smaller amygdala, cingulate,
and insula volumes. Although the exact mechanisms are
not clear, functional and structural changes in the insula,
cingulate, and amygdala have been widely documented in
cigarette smoking and other addictions16,17,35,46,47.We
found no associations of smoking with brain structures
that have been widely linked to dementia (hippocampus,
parahippocampal gyrus, entorhinal cortex, cuneus, and
precuneus). There was an association between smoking
and smaller entorhinal cortex; but it was not signiﬁcant
after adjustment for substance use/psychological or
respiratory factors. Overall, our regional analyses suggest
that, at mid-life, smoking seems to be related to emotion
and reward/ addiction-related candidate regions and
regions at the intersection of cognitive and reward path-
ways, such as insula, the cingulate, and the frontal and
temporal lobes. The frontal, cingulate, and insular regions
contain some of the highest densities of nicotinic acet-
ylcholine receptors48. Data from animal models suggest
that nicotine can have neurotoxic consequences such as
cell loss and synaptic alterations49–51. Cigarette smoking
also involves exposure to several toxic compounds,
including carbon monoxide, free radicals, and free oxygen
species, which can lead to cellular and oxidative damage
directly affecting neuronal and brain tissue11 and to
compromised inﬂammatory, respiratory, and vascular
systems resulting in deﬁcits in blood oxygen and nutrients
to the brain11,52. Alcohol use has also been linked to
oxidative damage and molecular and cellular impair-
ments11; combined smoking and alcohol use could thus
make the brain more vulnerable to each substances’
adverse consequences. It is interesting that we found an
interaction with alcohol use and not with other substance
use. This might be explained by a larger overlap in the
involvement of alcohol and smoking with dopaminergic
and γ-aminobutryic acid (GABA) and glutamate systems
in several brain regions including the thalamus, cingulate,
insula, amygdala, and frontal and temporal lobes53,54.
Additionally, unlike illicit drug use, alcohol use is more
frequent and legally and socially accepted, which could
lead to different proﬁles of addiction and users. Further,
there could be more potential stigma related to illicit drug
use that can inﬂuence the accuracy of self-reported use;
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the information on the extent of use was also limited in
our study and might not have well captured this behavior.
Finally, with the wider acceptability and availability of
alcohol, the interaction observed with alcohol use could
also be indicative of more contexts and scenarios facil-
itating a higher cigarette smoking and exposure.
Combined, results of the risk factors models and the
regional GM analyses suggest that behavioral and
substance-use mechanisms may be central to smoking
behavior at younger age and its relationships to GM
outcomes at mid-life. These data are in line with results
from recent epidemiological and clinical studies indicat-
ing that dual concurrent treatment for smoking and
alcohol/substance abuse is more effective for long-term
abstinence outcomes than treating each addiction sepa-
rately11,41,55. Importantly, our results suggest that neuro-
biological links between co-occurring smoking and
substance use behaviors with reward-network regions
may be underlying the observed synergy between these
behaviors in determining the severity of addictive symp-
toms and relapse.
Given the high prevalence of smoking and alcohol use,
their frequent co-occurrence, and the fact that they are
modiﬁable behaviors, our results emphasize the research,
clinical, and public health value of further understanding
the interplay between these two factors and how it affects
brain structures and functions across the life-course and
brain aging in late-life.
One limitation of our study is that we cannot exclude
the possibility that some brain differences observed
between smokers and never-smokers might have pre-
ceded and even predisposed to nicotine addiction, due to
factors such as early developmental processes related to
maternal smoking, a family history of addiction, or
exposure to stressors. Our study focused on cigarette
smoking and use of other forms of nicotine use was
limited (prevalence of cigar, pipe, smokeless tobacco use
in our sample was ≤4.3%) or not measured (e.g., e-
cigarette and water pipe use) in our sample. The small
number of subjects with certain vascular risk factors
might have limited the detection of interaction with
smoking. Similarly, the low prevalence of the use of spe-
ciﬁc illicit drugs (other than marijuana use) and the lack
of information on actual quantity and duration of use
limited our conclusions regarding the role of illicit drug
use and of different types of illicit drug use in the rela-
tionship of smoking with brain structures. We examined
several regions and there is the possibility of false posi-
tives. Applying a stringent Bonferroni correction for the
16 regional volumes investigated in the two alcohol sub-
groups (signiﬁcance level= 0.0016), the associations with
temporal, cingulate, and insula GM remain statistically
signiﬁcant. Overall, the relationships observed were
strong and consistent, which supports the overall message
that these ﬁndings merit further discussion and certainly
replication.
In conclusion, in community-dwelling middle-aged
adults, current smoking was associated with smaller total
and regional GM volumes. These associations were spe-
ciﬁcally observed in alcohol users, and were localized in
the temporal, frontal, insula, and amygdala volumes.
Findings suggest important connections between smoking
and behavioral co-morbidities and brain regions linked to
addiction processes at mid-life. Future research on
smoking and brain health, as well as interventions to
address smoking and alcohol use, should prioritize sub-
jects who present with both cigarette smoking and alcohol
use, as they appear to be at even greater risk for adverse
brain outcomes.
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